ACRS
Aclaris Therapeutics, Inc.
NASDAQ · Healthcare · Medical - Diagnostics & Research · US
$5.50
+1.85%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$5.41
From 52W high−15.90%
Volume4.69M
Market cap$809.59M
P/E (TTM)—
P/S (TTM)98.5x
Div yield—
Key dataSep 18, 2026
Open
$5.41
From 52W high
−15.90%
Volume
4.69M
Market cap
$809.59M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−9.6x
P/E (TTM)
—
RSI (14)
42.7
MomentumView details →
1D Return
+1.85%
YTD Return
+80.90%
SummaryUpdated Jun 1, 2026
Aclaris Therapeutics, Inc. (NASDAQ: ACRS) is a clinical-stage biopharmaceutical company founded in 2012 and headquartered in Wayne, Pennsylvania. The company went public in October 2015 and focuses on developing novel drug candidates for immune-inflammatory diseases. Aclaris operates through two business segments: a Therapeutics division that develops innovative therapies for significant unmet medical needs in immuno-inflammatory conditions, and a Contract Research segment that provides laboratory services to generate additional revenue while advancing its core drug development mission.
Similar companies
Latest newsMore news →